强生新冠疫苗保护率为66%
据外电报道,美国食品及药物管理局(FDA)表示,强生(JNJ.US)的新冠疫苗保护率为66%,考虑在本周向疫苗发出紧急使用许可。
该疫苗在一项4.4万人全球临床测验中,对预防中度至严重新冠肺炎的有效率为66%。在预防入院重症方面,接种疫苗後14日的保护率为85%,28日後更达到100%。至於预防南非变种病毒方面,有效率为64%。
强生表示,在获得FDA批准後,预计将有400万剂疫苗准备投产,并会在3月底之前运送2,000万剂,承诺到6月底向美国提供1亿剂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.